Montgomery County (MOCO), Maryland, sits at the epicenter of biopharma growth, investment, and innovation that makes the BioHealth Capital Region (BHCR) one of the top bio clusters in the world.
After spending the past five years fostering economic development in Montgomery County, Sarah Miller is turning her attention to the biopharma industry and the BioHealth Capital Region. Starting May 3, Miller joined BioHealth Innovation, Inc. as Vice President of Economic Development.
Connected DMV, a Driving Force Behind Montgomery County’s New Global Pandemic Prevention and Biodefense Center
Identifying gaps and bridging them—that’s what Connected DMV’s President and CEO Stu Solomon does best. And now he and his partners are turning their attention to one of the globe’s most important and challenging divides: Preparing for the next pandemic.
A free, virtual Forum focused on the growing Digital Health industry in the Baltimore/Washington region and beyond, presented by EAGB & BHI. About this Event The Economic Alliance of Greater [….]
VIRTUAL SBIR and OTHER NON-DILUTIVE FUNDING SOURCES WORKSHOP with 1:1 PARTNERING – March 17-19, 2021
Don’t miss a unique opportunity to discuss your biohealth technology innovation directly with Program Officers from NSF, various institutes at NIH, the University of Maryland MIPS program, and others.
Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. Join us for the 7th Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.
Vanderbilt Scientist Life’s Work Laid the Foundation for a Global Pandemic Prevention and Bioterrorism Center
Dr. James Crowe Jr., Director, Vanderbilt Vaccine Center, Professor of Pediatrics and Pathology, Microbiology and Immunology, Ann Scott Carell Chair, and his team have spent the past decade preparing for the next global health epidemic.
The BioHealth Capital Region (BHCR) had a remarkable 2020, and there is palpable momentum and excitement in the air as we approach the end of Q1 2021. How will the pandemic impact the region’s push to be “Top 3 by 2023?” Where will this significant momentum lead? These questions are yet to be answered.
Akan Biosciences Announces FDA Acceptance of IND Application for StroMel™; in Osteoarthritis of Knee
StroMel™ is a proprietary adipose-derived Stromal Vascular Fraction (SVF) product. StroMel™ will be frozen and stored allowing multiple administrations with each lot. Although the current IND is for autologous administration, Akan is planning to explore allogeneic applications as well.
2020 is over, but its impact on how employers recruit and hire talent will reverberate for years to come.